Cargando…
Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects
BACKGROUND AND OBJECTIVE: Dabigatran etexilate (DE) is an anticoagulant with proven efficacy and tolerability for stroke prevention in patients with non-valvular atrial fibrillation. For the commercial capsule, a complex formulation is used to maintain the acidic microenvironment required for maxima...
Autores principales: | Harada, Akiko, Ikushima, Ippei, Haranaka, Miwa, Yanagihara, Aki, Nakayama, Daisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266796/ https://www.ncbi.nlm.nih.gov/pubmed/31667735 http://dx.doi.org/10.1007/s40256-019-00377-x |
Ejemplares similares
-
Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions
por: Li, Xin, et al.
Publicado: (2020) -
The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013) -
Dabigatran etexilate tetrahydrate
por: Liu, Hong-Qiang, et al.
Publicado: (2012) -
Estimation Based on Emission Wavelength of Dabigatran Etexilate Mesylate in Bulk and Capsule Dosage Form
por: Anumolu, P. D., et al.
Publicado: (2016) -
New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)